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Abstract
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although
efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been
unsuccessful1-3, a minority of individuals naturally develop these antibodies after many years of
infection4-7. How such antibodies arise, and the role of viral evolution in shaping these responses,
is unknown. Here we show, in two HIV-1–infected individuals who developed BCN antibodies
targeting the glycan at Asn332 on the gp120 envelope, that this glycan was absent on the initial
infecting virus. However, this BCN epitope evolved within 6 months, through immune escape
from earlier strain-specific antibodies that resulted in a shift of a glycan to position 332. Both
viruses that lacked the glycan at amino acid 332 were resistant to the Asn332-dependent BCN
monoclonal antibody PGT128 (ref. 8), whereas escaped variants that acquired this glycan were
sensitive. Analysis of large sequence and neutralization data sets showed the 332 glycan to be
significantly underrepresented in transmitted subtype C viruses compared to chronic viruses, with
the absence of this glycan corresponding with resistance to PGT128. These findings highlight the
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dynamic interplay between early antibodies and viral escape in driving the evolution of conserved
BCN antibody epitopes.
Although the role of glycans in shielding neutralizing epitopes has long been known9-11, it
has only recently become clear that many BCN responses directly target glycans, including
the one at position 332 in the C3 region of the gp120 subunit of the HIV-1 envelope
protein8,12-18. The recent isolation of monoclonal antibodies (mAbs) that target this glycan,
which are the most potent yet described, has focused attention on this epitope8. These mAbs
(PGT121–PGT123, PGT125–PGT128, PGT130, PGT131 and PGT135–PGT137) neutralize
effectively across all HIV-1 subtypes, with the broadest, PGT128, neutralizing >70% of
viruses tested8. Crystal structures of PGT127 and PGT128 have shown that these mAbs
penetrate the glycan shield, recognizing high-mannose glycans at amino acids 301 and 332,
in addition to a short β-strand in the C terminus of the V3 loop19. The conserved nature of
these amino acids and the high potency of this class of mAbs suggest that this region may be
an important vaccine target. Furthermore, this epitope is immunogenic, as Asn332-
dependent BCN antibodies are often found in infected subjects who develop neutralization
breadth8,14-17. However, as with other BCN antibodies, the factors that favor the emergence
of Asn332-dependent BCN antibodies remain unclear. Here we hypothesize that the
evolution of viral populations, which are under considerable immune and fitness selection
pressures, creates BCN antibody epitopes essential for the development of neutralization
breadth.
From a cohort of 79 HIV-1 subtype C-infected women studied starting at the point of acute
infection, we focused on two participants who developed Asn332-dependent BCN
antibodies. Subject CAP177 produced antibodies by 3 years after infection that were capable
of neutralizing 88% of a large multisubtype panel of 225 heterologous viruses (M. Lacerda,
P.L.M., N. N., M.S.S., E.S.G. et al., unpublished data). The second individual, CAP314,
neutralized 46% of 41 heterologous viruses after only 2 years of infection (Supplementary
Fig. 1). Plasmas from CAP177 and CAP314 were unable to neutralize heterologous viruses
that lacked the glycan at position 332 from the time when BCN responses were first detected
and thereafter (Fig. 1a), confirming that their BCN activity depended on the 332 glycan,
similar to the PGT128 mAb.
Single-genome amplification and gp160 sequencing from plasma viral RNA (Online
Methods) was used to determine the amino acid sequence of the envelopes of circulating
viral populations at multiple time points. This included the earliest available plasma
samples, which were taken 2 weeks after infection for CAP177 (enabling inference of the
transmitted/founder virus20) and 3 months after infection for CAP314. In both cases, these
acute viruses lacked the predicted N-linked glycan at amino acid 332, although almost all
sequences contained an intact glycosylation site at position 334 (Fig. 1b,c). By 5–6 months
of infection, a glycan at position 332 evolved in both CAP177 and CAP314 through an
N334T or N334S substitution, which also resulted in the destruction of the neighboring
glycan at position 334. By 12–15 months, when BCN antibodies became detectable, the 332
glycan was present in all sequences; however, at around 2 years the glycan reverted to
position 334, most likely as a consequence of viral escape from the Asn332-dependent BCN
response (Fig. 1b,c). Therefore, for both CAP177 and CAP314, the glycan that formed the
basis of the BCN epitope was not present on the infecting virus but evolved shortly
thereafter, coincident with the appearance of strain-specific antibodies (Fig. 1c).
The 332 glycan lies within the C3 region, which is highly immunogenic in HIV-1 subtype C
and is often targeted by early strain-specific antibodies21. Indeed, we have previously shown
that in CAP177 early neutralizing antibodies targeted the C3 region22. As viral escape often
involves glycan rearrangements10, we postulated that the shift of a glycan from position 334
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to 332 in CAP177 and CAP314 may have been the result of neutralization escape from early
strain-specific antibodies. To test this, we cloned the acute virus and a representative 6-
month virus from CAP177 and CAP314 and inserted the 332 glycan into the acute clones by
mutating the asparagine at position 334 to a serine (which also deleted the glycan at 334).
We tested all three viruses from both individuals for sensitivity to autologous plasma from 6
months after infection. We detected autologous neutralizing responses against the acute
viruses, whereas the 6-month clones were resistant to contemporaneous plasma, as expected
(Fig. 2a,b). Introduction of the glycan at position 332 resulted in almost complete resistance
to neutralization by plasma from CAP177 and reduced neutralization sensitivity to plasma
from CAP314, suggesting that the 332 glycan evolved to afford escape from early strain-
specific antibodies.
The absence of the glycan at position 332 on the acute viruses from CAP177 and CAP314
suggested that they might be resistant to BCN mAbs that depend on this glycan, such as
PGT128. Neutralization experiments showed that CAP177 and CAP314 acute clones were
resistant to PGT128, whereas the 6-month clones that contained the 332 glycan were highly
sensitive, with a half-maximum inhibitory concentration (IC50) <0.06 μg ml−1 (Table 1).
We obtained similar data with a related mAb, PGT121, although the CAP177 acute clone
showed moderate sensitivity (0.21 μg ml−1) but was nevertheless 20-fold more resistant
compared to the 6-month clone. Both N334S mutants (acute clones with a glycan introduced
at position 332) were sensitive to PGT121 and PGT128, confirming the role of the 332
glycan in conferring sensitivity to these mAbs. None of the CAP177 or CAP314 clones was
sensitive to the mAbs PGT135 or 2G12 (Table 1), which depend on additional glycans at
other amino acids, that are uncommon among subtype C viruses23-27. Thus, whereas shifting
a glycan from position 334 to 332 allowed the virus to escape autologous neutralizing
antibodies, this created a new neutralizing antibody epitope that provided the antigenic
stimulus to elicit BCN antibodies targeting the 332 glycan.
We assessed whether this pattern of selection of the 332 glycan was evident at a population
level using more than 7,300 single-genome amplification—derived gp160 envelope
sequences from acute and chronic HIV-1 infections (Online Methods)20,28. Sequences with
evidence of dual infection were excluded. For each subject, the consensus sequence was
generated and the frequency of the 332 glycan was determined. We assessed significance
with Fisher’s exact test. In subtype C, the 332 glycan was significantly less common among
transmitted/founder viruses (45/68, 66%) compared to unmatched chronic viruses (52/62,
84%, P = 0.0166, Fig. 3a). To ensure that this was not due to adaption of HIV to neutralizing
antibodies over the course of the epidemic time29, we performed the same analysis using a
smaller data set of 502 matched sequences from 20 individuals, with similar results (P =
0.0457, Fig. 3a). Although we observed the same trend in subtype B sequences, it was not
statistically significant (Fig. 3a). Taken together, these results suggest that the pattern of
evolution we describe for CAP177 and CAP314 may be relatively common and that the
absence of the 332 glycan on subtype C viruses may provide an advantage during
transmission or early viral outgrowth.
We analyzed the phenotypes of 101 transmitted/founder subtype C viruses using envelope
clones generated as part of the Vaccine Immune Monitoring Core Standard Virus Panel
Consortium. For this, transmitted/founder envelope sequences were inferred from
singlegenome amplified and sequenced envelope amplicons derived from plasma from
acutely HIV-infected subjects30 and cloned into a mammalian expression vector. Envelope
clones were transfected into 293T cells with the HIV backbone construct pSG3ΔEnv to
produce envelope pseudotyped particles, and neutralization assays were performed in TZM-
bl cells as described in the Online Methods. Phenotypic analysis supported the genotypic
analysis, with a high proportion (46%) of viruses resistant to PGT128 neutralization at the
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highest concentration tested (10 μg ml−1) (Fig. 3b and Supplementary Fig. 2). Resistance
strongly correlated with the absence of the 332 glycan (P < 0.0001) (Fig. 3c), although some
viruses that contained the glycan were also resistant, consistent with the fact that additional
residues are needed to form this epitope8. Of 31 viruses in which the glycan at position 332
was absent, only three showed neutralization sensitivity. Of these, two contained the glycan
at position 295, which is very rare in subtype C viruses26 but structurally proximal to the
332 glycan and shown by mutagenesis to affect the PGT128 epitope19. Although this virus
panel was tested only against PGT128, resistance to this mAb generally extends to other
Asn332-dependent PGT mAbs8. These data suggest that Asn332-dependent antibodies
present either through passive immunotherapy or vaccination might be only partially
effective in preventing subtype C infections and that combinations of antibodies targeting
different epitopes may need to be tailored to match circulating viral variants24,26,31.
In addition to the Asn332-dependent epitope, a second BCN antibody epitope that includes
the glycans at amino acid positions 156 and 160 in the V2 region has been defined by the
mAbs PG9, PG16 (ref. 18) and PGT145 (ref. 8). To assess whether epitope evolution was
also associated with the appearance of Asn160-dependent BCN antibodies, we studied two
individuals, CAP8 and CAP256, who developed this specificity15 (Supplementary Fig. 3a).
In both cases, the glycan at amino acid 160 was absent from envelope sequences at
transmission but appeared at 6 and 3 months in CAP8 and CAP256, respectively, suggesting
a pattern of evolution similar to that observed with 332 glycan (Supplementary Fig. 3b).
Furthermore, we found acute viruses to be resistant to BCN mAbs PG9, PG16 and PGT145,
whereas later clones that contained the 160 glycan became sensitive to PG9 and PGT145,
although not to PG16 (Supplementary Fig. 4). However, although insertion of the 160
glycan by site-directed mutagenesis into the resistant acute clones rendered them sensitive to
PG9 and PGT145, unlike the case with the CAP177 and CAP314 mutants containing the
332 glycan, this single change did not mediate neutralization escape. It was also not possible
to show selection of the 160 glycan using large sequence data sets, as it is highly conserved
in both acute and chronic sequences (Supplementary Fig. 5).
Despite the fact that BCN epitopes are highly conserved, they only occasionally elicit BCN
responses in humans. Those targeting epitopes centered around the 332 or 160 glycans
develop more frequently in infected people compared to BCN antibodies directed at the CD4
binding site or membrane-proximal region12-14. The data presented here raise the hypothesis
that, at least in the case of Asn322-directed antibodies, viral evolution may facilitate their
elicitation. However, the absence of these glycans on the acute virus is not a prerequisite for
the development of breadth, nor does the evolution of a BCN epitope guarantee that these
antibodies will arise. Indeed, within this cohort, examples of both scenarios exist
(Supplementary Fig. 6a,b). Furthermore, in a study of a SHIV-infected macaque32 where the
332 glycan was present at transmission, potent and broad Asn332-dependent BCN
antibodies developed within 9 months. In HIV-1 subtype C viruses, where the absence of the
332 glycan is favored at transmission, subsequent immune pressure exerted by strain-
specific neutralizing antibodies results in the evolution of the 332 glycan. This process
provides a mechanism for the evolution of BCN epitopes, with neutralization escape driving




CAP177, CAP8 and CAP256 were part of the CAPRISA 002 Acute Infection study, a
cohort of 245 high-risk, HIV-negative women that was established in 2004 in Durban, South
Africa, for follow-up and subsequent identification of HIV seroconversion33. These three
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HIV-infected subjects were among the seven women in this cohort who developed
neutralization breadth15. The fourth individual, CAP314, was enrolled in the CAPRISA 004
trial, a two-arm, double-blind, randomized, placebo-controlled trial, conducted from May
2007 to March 2010, to assess the effectiveness and safety of tenofovir gel for the
prevention of HIV infection in women34. Monitoring BCN antibodies in this cohort of 39
women showed that she was one of three who developed breadth by 2 years of infection,
two of whom targeted an Asn332-dependent epitope. The CAPRISA 002 Acute Infection
study was reviewed and approved by the research ethics committees of the University of
KwaZulu-Natal (E013/04), the University of Cape Town (025/2004) and the University of
the Witwatersrand (MM040202). The CAPRISA 004 trial was approved by the University
of KwaZulu-Natal’s Biomedical Research Ethics Committee (E111/06), Family Health
International’s Protection of Human Subjects Committee (9946) and the South African
Medicines Control Council (20060835). All participants provided written informed consent.
Single-genome amplification and sequencing
HIV-1 RNA was isolated from plasma using the Qiagen QIAamp Viral RNA kit and reverse
transcribed to cDNA using SuperScript III Reverse Transcriptase (Invitrogen, CA). The
envelope genes were amplified from single-genome templates30, and amplicons were
directly sequenced using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems, Foster City, CA) and resolved on an ABI 3100 automated
genetic analyzer. The full-length env sequences were assembled and edited using
Sequencher version 4.0 software (Genecodes, Ann Arbor, MI). The number of potential N-
linked glycosylation sites was determined using N-glycosite (http://www.hiv.lanl.gov/
content/sequence/GLYCOSITE/glycosite.html/). Multiple sequence alignments were
performed using Clustal X (version 1.83) and edited with BioEdit (version 5.0.9) Sequence
alignments were visualized using Highlighter for Amino Acid Sequences version 1.1.0
(beta). Selected amplicons were cloned into the expression vector pcDNA 3.1 (directional)
(Invitrogen) by reamplification of SGA first-round products using Phusion enzyme (Finn
Enzymes) with the EnvM primer35 and the directional primer EnvAdir21. Cloned env genes
were sequenced to confirm that they exactly matched the sequenced amplicon.
Site-directed mutagenesis
Sensitive heterologous viruses Q23, Du156, TRO.11, CAP200 and ConC were mutated at
key residues (332–334 or 160–162) by site-directed mutagenesis using the Stratagene
QuickChange II kit (Stratagene) as described by the manufacturer. Mutations were
confirmed by sequencing. Autologous clones derived from CAP177 and CAP314 were
mutated to shift the glycan from position 334 to 332, and mutants were verified by
sequencing. Similarly autologous clones from CAP8 and CAP256 were mutated to introduce
the glycan at position 160, and mutants were verified by sequencing.
Neutralization assays
The JC53bl-13 (TZM-bl) cell line was obtained from the NIH AIDS Research and
Reference Reagent Program. 293T cells were obtained from G. Shaw. Both cell lines were
cultured in DMEM (Gibco BRL Life Technologies) containing 10% heat-inactivated FBS
and 50 μg/ml gentamicin (Sigma). Cell monolayers were disrupted at confluency by
treatment with 0.25% trypsin in 1mM EDTA. Env-pseudotyped viruses were obtained by
co-transfecting the Env plasmid with pSG3ΔEnv10 using FuGENE transfection reagent
(Roche) as previously described36. Neutralization was measured as described36 by a
reduction in luciferase gene expression after single-round infection of JC53bl-13 cells with
Env-pseudotyped viruses. Titers were calculated as the reciprocal plasma dilution (ID50)
causing 50% reduction of relative light units (RLU).
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Characterizing the antibody specificities and viral populations in CAP177 and CAP314. (a)
Serial plasma neutralization of three heterologous viruses (Q23, Du156 and TRO.11 for
CAP177 and Q23, Du156 and CAP200 for CAP314) compared to mutant viruses where the
332 glycan was deleted by mutagenesis. Wild-type viruses are shown in orange and mutants
in blue. (b) Sequence alignment showing part of the C3 region from 2 weeks (CAP177) or 3
months (CAP314) up to 28–30 months after infection. The number of sequences at each
time point is indicated. Gray shading indicates the presence of a predicted N-linked glycan,
and dashes indicate sequence identity compared to the acute sequence. HXB2 numbering is
used throughout. (c) The frequency of the 332 glycan is shown over time (as pie charts)
relative to neutralization of the acute autologous virus (corresponding to the 2-week and 3-
month sequences shown above, gray line) and sensitive heterologous viruses (of subtype C
in orange, subtype B in blue and subtype A in green). Plasma samples were available only
up to 2 years after infection for CAP314, who received antiretroviral therapy shortly
thereafter.
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The glycan at position 332 mediates neutralization escape in CAP177 and CAP314. (a)
Partial sequence alignment showing the CAP177 acute virus (CAP177 2 weeks), a
representative 6-month clone (CAP177 6 months) and the acute virus mutated to contain a
glycan at position 332, which deletes the glycan at position 334 (CAP177 2 weeks N334S).
All three clones were tested for neutralization sensitivity to autologous serum from 6 months
after infection. (b) Partial sequence alignment showing the CAP314 acute virus (CAP314 3
months), a representative 6-month clone (CAP314 6 months) and the mutated virus
(CAP314 3 months N334S) and their sensitivity to autologous serum from 6 months after
infection. Residual neutralization of the CAP314 3 months N334S mutant reflects the
presence of neutralizing antibody specificities targeting other epitopes, as described
previously22. Experiments were performed three times, and error bars represent the s.e.m.
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The glycan at residue 332 is underrepresented in subtype C transmitted/founder viruses,
which are also frequently resistant to the PGT128 mAb. (a) Comparison of the frequency of
the 332 glycan among 1,371 envelope sequences from 68 subjects with HIV-1 subtype C
acute or early infection20 and 1,111 sequences from 62 subjects with chronic HIV-1 subtype
C infections (L.P., S. Joseph, J. Anderson, M.-R.A., J. Salazar-Gonzalez et al., unpublished
data). We also analyzed a smaller data set of matched sequences (502 sequences from 20
subjects from the CAPRISA cohort), and compared acute sequences to those from the same
individual at 1 year after infection. For subtype B, a published data set of 2,715 acute
sequences from 88 subjects and 2,122 sequences from 86 chronic infections was used28. (b)
Neutralization sensitivity of 101 transmitted/founder viruses to neutralization by the
PGT128 mAb. (c) Neutralization sensitivity of subtype C transmitted/founder viruses
correlated strongly with the presence or absence of the 332 glycan. Colors reflect
neutralization IC50 titers >10 μg ml−1 (blue), 1–10 μg ml−1 (yellow), 0.1–1μg ml−1 (orange)
and <0.1 μg ml−1 (red).
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Table 1
Neutralization of CAP177 and CAP314 pseudoviruses by BCN monoclonal antibodies
mAb (IC50 titers) PNG 332 PGT121 PGT128 PGT135 2G12
CAP177 2 weeks − 0.21 >10 >10 >10
CAP177 6 months + 0.01 0.06 >10 >10
CAP177 2 weeks N334S + 0.04 0.71 >10 >10
CAP314 3 months − >10 >10 >10 >10
CAP314 6 months + 0.03 0.03 >10 >10
CAP314 3 months N334S + 0.03 0.07 >10 >10
TRO.11 (control) + 0.03 0.06 0.16 0.49
Donor subtype A CRF02_AG C B
Breadth
a 70%8 72%8 33%8 41%24
a
Percentage of viruses neutralized with IC50 <50 μg ml−1. Sensitivity of CAP177 and CAP314 clones to neutralization by Asn332-dependent
BCN monoclonal antibodies. The acute, 6-month and N334S mutant viruses from both CAP177 and CAP314 were tested against mAbs PGT121,
PGT128, PGT135 and 2G12 in a TZM-bl neutralization assay. Colors reflect neutralization IC50 titers >10 μg ml−1 (blue), 0.1–10 μg ml−1
(orange) and <0.1 μg ml−1 (red). TRO.11, a subtype B virus containing the glycan at residue 332, was included as a positive control. For the
mAbs, the subtype of the donor from which they were isolated together with published data on their neutralization breadth is also included.
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